India ahead of China in global pharma industry
India was better positioned than China on various parameters to reach the centre stage in the global pharma industry, but needed to address issues like infrastructure and pollution to maintain the momentum, Ranbaxy Chief Mentor Brian Tempest said ...
By PTI |
MUMBAI: India was better positioned than China on various parameters to reach the centre stage in the global pharma industry, but needed to address issues like infrastructure and pollution to maintain the momentum, Ranbaxy Chief Mentor Brian Tempest said on Thursday.
Addressing a CII-meet on pharmaceutical industry here, he said the country was moving ahead at a rapid pace in the global arena and has the potential to become a 'global strategic asset' for the pharma industry.
"India's 50 per cent population below the age of 25 years is going to act as a secret weapon in future, while the one- child policy in China will play a spoilsport," he said, economic fundamentals are also expected to favour India in the days to come.
Maintaining that all the fundamentals were very strong in India and the regulatory framework has, over the years, changed a lot for the better, he said qualified scientists and engineers have made it a better place for R&D investments.
"However, infrastructure is a potential risk for India and if it does not improve in the next three to four years, it will really limit the growth of the industry," Tempest said.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
